Dan Auclair (@auclairdan.bsky.social)

Congrats for this important work. CEPHEUS study of Dara+VRd vs. VRd: MRD-negativity 60.9% for quad vs. 39.4% w/ VRd; ≥CR rates 81.2% vs. 61.6%; sustained MRD negativity (≥12 mos) 48.7% vs. 26.3%, 43% lower progression or death risk #MyelomaSky @szusmani.bsky.social pubmed.ncbi.nlm.nih.gov/39910273/

loading . . .

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study - PubMed Frontline daratumumab-based triplet and quadruplet standard-of-care regimens have demonstrated improved survival outcomes in newly diagnosed multiple myeloma (NDMM). For patients with transplant-ineli... https://pubmed.ncbi.nlm.nih.gov/39910273/